Document is current

Article History

First Online: 3 February 2025

Declarations

:

: Not applicable.

: All authors received honorarium from Kyowa Kirin International to present at the XLH Matters 2023 meeting. LS has received honoraria for lectures and advice from Alexion/AstraZeneca, Amgen, AM-Pharma, BioMarin, Chiesi, Gedeon Richter, GlaxoSmithKline, Inozyme, Ipsen, Kyowa Kirin, Medi, Novartis, STADA Pharm, Theramex and UCB. He has also received grants for scientific projects from Alexion/AstraZeneca, Chiesi, Kyowa Kirin and Novartis. FA has no additional conflicts of interest. CAH has received lecture fees for Kyowa Kirin meetings and is an investigator in the XLH Registry study. PAS has no additional conflicts of interest. MBD has received lecture fees from Alexion and Kyowa Kirin, and a research grant from Kyowa Kirin. SDS has received honoraria and travel grants from Kyowa Kirin and has participated as a sub-investigator in clinical trials for burosumab and in the XLH Registry. She is also a primary investigator in a clinical trial for ustekinumab in children with diabetes. FE has received consultancy fees from Alnylam, Avrobio, Chiesi Pharmaceuticals, Otsuka Pharmaceuticals and Recordati Rare Diseases. OG is chair of the IXLHA, and the IXLHA has received unrestricted grants from Kyowa Kirin, Novo Nordisk, and Ultragenyx. MKJ has received honoraria, grants, travel and/or subsistence expenses from Amgen Ltd, UCB, Kyowa Kirin, AbbVie, Sanofi, Hakim and Besin Healthcare. RMFS has received consulting fees from Kyowa Kirin and QED Therapeutics. AR has received grants from Kyowa Kirin, and honoraria from Ipsen and Ferring. KR has participated in an advisory board for MED-EL and Munich-Surgical Imaging. He has also received research funding from MED-EL and Storz, and travel grants from MED-EL, Cochlear and Advanced Bionics. JSB has received speaker and consultancy fees from Alexion, Amgen, Kyowa Kirin and UCB. MSC has received honoraria from Kyowa Kirin for taking part in advisory boards, delivering presentations and for funding of clinical staff for the rare bone service at Evelina London Children’s Hospital and Great Ormond Street Hospital. She has also been an investigator on trials for burosumab and the International XLH Registry, funded by Kyowa Kirin. SSBN has received payments for invited speeches, consultancy and research grants from Kyowa Kirin. She has also received payments for consultancy from Inozyme and Novo Nordisk. GTM has received consultancy fees from BioMarin and Kyowa Kirin. AL has received fees through her institution for a Phase I/II trial from Kyowa Kirin, and has also received honoraria from Alexion, Novo Nordisk, Ipsen and Pfizer International.